Printer Friendly

Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid [alpha]-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Pompe disease (PD), [6] or glycogen storage disease type II, is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of lysosomal acid a-glucosidase (GAA, EC Classic infantile-onset Pompe disease (IOPD) presents in early infancy with hypertrophic cardiomyopathy, generalized muscle weakness, and failure to thrive. Patients with IOPD usually die within the first year of life from respiratory failure if not treated with enzyme replacement therapy. Late-onset Pompe disease (LOPD) is characterized by muscle weakness and respiratory insufficiency with onset ranging from childhood to adulthood, and a variable rate of disease progression. There is also a nonclassical infantile form with no cardiomyopathy (1-4).

Studies from the Taiwan newborn screening program showed that early initiation of enzyme replacement therapy in IOPD patients led to reversal of glycogen storage in muscle and restoration of cardiac size and function (5, 6). Long-term follow-up of these patients showed that they remained ventilator free with stable cardiac function and essentially normal motor development up to 90 months (7). Pompe disease was added to the Recommended Uniform Screening Panel in 2015. Measurement of GAA activity in dried blood spots by tandem mass spectrometry (MS/MS) (8), by fluorometry (9), or by digital microfluidic fluorometry (10) have been used for newborn screening of Pompe disease. In addition to detecting individuals with true Pompe disease, infants with low GAA due to pseudodeficiency, carrier status and variants of unknown significance (VOUS) are also detected. These screening assays cannot determine the clinical phenotype based on their enzyme activity measurements (11). A reliable and accurate post-newborn screening GAA enzyme analysis that can accurately measure low residual activity is needed. Such an assay with glucosidase alpha, acid (GAA) mutations and clinical findings would be important in guiding the management of screen positive individuals.

GAA hydrolyzes the terminal a-linked glucose residues in short polymers of glucose that are formed as remnants during breakdown of high molecular weight glycogen in tissues, especially in muscle and liver. Like GAA, maltase-glucoamylase present in leukocytes is also active at acidic pH on these substrates, and thus it was not initially possible to selectively measure GAA activity in whole blood. More recently, acarbose has been discovered as a selective inhibitor of maltase-glucoamylase, thus allowing newborn screening for Pompe disease using dried blood spots (8, 12). The classic GAA assay uses the fluorometric substrate 4-methylumbelliferyl-a-glucoside. Recent studies have shown that the analytical range of this assay, defined as the ratio of assay response measured with the normal control to that due to all GAA-independent processes, is relatively small compared to the corresponding value obtained with MS/MS assays (13), mainly due to the intrinsic fluorescence of the substrate itself (13). The low analytic range may be the reason that the fluorometric assay is unable to differentiate between IOPD vs LOPD in blood samples (14, 15). Evidence that residual GAA activity is correlated with the age of onset of Pompe disease comes from studies with skin fibroblasts (16, 17).

The analytical range of an LC-MS/MS assay was recently shown to be nearly 2 orders of magnitude higher than that for the fluorometric enzyme assay (13). Here we describe a new LC-MS/MS method to accurately measure residual GAA activity in leukocytes isolated from venous blood of healthy individuals, carriers, patients carrying 1 or more pseudodeficiency alleles, and Pompe patients with a range of severity. We also studied GAA activity in immortalized B lymphocytes from Pompe patients with known age of onset of symptoms. Side-by-side comparative studies with the standard fluorometric assay were also carried out.



Ammonium formate, acarbose, and formic acid were purchased from Sigma-Aldrich. CHAPS detergent was from Fisher Scientific. The substrate (S) and internal standard (IS) mixture for GAA was provided by the CDC. Reagents can now be obtained from PerkinElmer. Red blood cell lysis buffer for leukocyte extraction was from Qiagen.


The S/IS mixture of GAA was dissolved in 0.1 mol/L ammonium formate buffer containing 12 [micro]mol/L acarbose and 1 g/L CHAPS at pH 4.0 to afinal concentration of 0.56 mmol/L for substrate and 5.6 [micro]mol/L for IS.


Five to 10 mL blood collected in an acid citrate dextrose tube is the preferred specimen type for GAA enzyme analysis. Other anticoagulants such as EDTA or sodium heparin tubes are also acceptable. For an infant, 1-3 mL blood collection can be attempted. The normal controls, most of the carriers and individuals who were homozygous for the common pseudodeficiency allele [p.G675S_p.E689K] used for this study were de-identified samples from the Mount Sinai Genetic Testing Laboratory. Seven infant carriers were referred from newborn screening. A total of 4 patients with IOPD were included in this study. One was a known patient on enzyme replacement therapy treatment (IOPD-1). Blood was collected before the infusion. The other 3 patients were identified and confirmed from the New York State Pompe newborn screening. All had increased creatine kinase activity and cardiomyopathy. In the LOPD cohort (n = 19), 3 were adults (LOPD-4, 6, and 7). LOPD-4 and 6 were homozygous for the common splice site mutation c.-32-13T>G, the genotype associated with LOPD (18, 19). Both individuals had normal creatine kinase activity and no symptoms at the time of sampling. LOPD-7 had fatigue and increased creatine kinase activity and transaminases for a few years before diagnosis. Sixteen patients (including 1 sibling) were diagnosed from New York State Pompe newborn screening and predicted to be potential LOPD patients by GAA mutation status and reduced enzyme activity (Table 1). Ethical approval was obtained from the Icahn School of Medicine at Mount Sinai Institutional Review Board. Fibroblast and immortalized B-lymphocyte samples, including normal, IOPD, and LOPD samples, were from the Coriell Cell Repositories (Camden, NJ).


The CDC provided the calibration standard mixtures of product (P) and IS (P/IS) at ratios of 0, 0.05, 0.1, 0.5, 1, 2, and 5. Full calibration was performed every 6 months. The normal control pool was prepared by pooling the lysates from previously tested negative samples. The affected control pool was prepared by heating the pooled normal lysate at 70 [degrees]C for 2 h to inactivate GAA activity. Included in every batch was the P/IS (1/1) calibrator, the normal control, the affected control, and a blank sample.


We added 3 parts of room temperature red blood cell (RBC) lysis solution to 1 part blood and mixed gently by inverting the tube 10 times. After incubating the sample for 10 min at ambient temperature, the samples were mixed again by inversion 10 times. The tubes were centrifuged for 5 min at 600g, the supernatant decanted, and the remaining pellet vortex-mixed for 5 s to disrupt the pellet. Then 5 mL of ice-cold deionized water was added and the tube vortex-mixed for 10 s to lyse the leftover RBC. Five milliliters of ice-cold 1.8% NaCl was added to restore isotonicity, the tube vortex-mixed for 10 s, and then the mixture centrifuged at 600g for 5 min. The supernatant was decanted and the pellet washed once more as above. After final centrifugation, the pellet was stored at -20 [degrees]C until analysis.


On the day of enzyme assay, the frozen leukocyte pellet was thawed at room temperature and then kept on ice throughout the remainder of the process. We added 0.3-0.6 mL of ice-cold normal saline (0.9% NaCl) depending on the size of the pellet and then vortex-mixed to resuspend the pellet. Using a QSonica Q700 sonicator, set to amplitude 3% and process time 6 pulses (1 s/pulse), the pellet was sonicated with 6-8 pulses to disperse the pellet homogenously. Using a transfer pipette, lysates were transferred to a labeled 1.5 mL microfuge tube and centrifuged for 10 min at 400g.


We pipetted 10 [micro]L of blank, bovine serum albumin standards (0.2, 0.5, 0.75, 1.0, 1.25,1.5 g/L), quality controls, and sample lysates into 96-well plate. After adding 25 [micro]L of protein assay reagent A (Bio-Rad) to each well, the plate was vortex mixed for 60 s at 600 rpm. We then added 200 [micro]L of protein assay reagent B (Bio-Rad) to each well, followed by incubation at ambient temperature for 10 min. The absorbance of the blue color product was read at 750 nm on a Varioskan Flash microplate reader.


Ten microliters of leukocyte lysate (containing 2-10 mg of protein) was incubated with 25 [micro]L of assay cocktail at 37 [degrees]C for 1 h. The reaction was quenched with 100 [micro]L of methanol/ethyl acetate (1:1, v/v) and followed by liquid-liquid extraction with 400 [micro]L ethyl acetate and 400 [micro]L water. One hundred microliters of the organic layer was transferred to a new 96-well plate and dried under nitrogen. The final sample was reconstituted in 200 [micro]L of methanol.


An Agilent 6460 LC-MS/MS system was used. An Agilent Zorbax C18 reversed-phase column (50 mm X 2.1 mm internal diameter, 1.8-[micro]m particle size) was maintained at 30 [degrees]C. Mobile phase A consisted of 5% acetonitrile with 0.1% formic acid and mobile phase B consisted of 1:1 methanol: acetonitrile with 0.1% formic acid. The LC conditions and MS parameters are described in the Supplemental Material file that accompanies the online version of this article at http://www. The extracted ion chromatograms of P and IS of 6 enzymes including GAA can be viewed in online Supplemental Fig. 1.


Full details of fluorometric and LC-MS/MS GAA assays in leukocytes and B-lymphocytes are provided in the online Supplemental Material file.



GAA stability was tested in blood samples stored in Vacutainer Tubes (BD Diagnostics) and in leukocyte lysates. Blood was collected into multiple tubes from 4 healthy donors and maintained at ambient temperature. The leukocytes were extracted immediately after sample collection, and 24, 48, 72, 96, and 120 h after blood collection. The mean (SD) GAA activity was 92.3% (10.2%) (24 h), 82.9% (16.4%) (48 h), 68.9% (14.0%) (72 h), 70.3% (15.2%) (96 h), and 49.0% (8.6%) (120 h) of the freshly processed leukocyte samples (Fig. 1A). Although this reduction would probably not cause a normal activity to erroneously enter into the affected range, it is important that the specimen be received and processed within 72 h of the blood draw. When an intermediate enzyme reduction is observed, a reference enzyme activity should be assessed. Random leukocyte lysates (n = 9) were assayed immediately after sonication and after storage at -80 [degrees]C. The lysates were tested again after 1 freeze--thaw or 2 freeze--thaw cycles to determine GAA stability. The GAA activities were 86.5 (8.9%) and 81.6 (9.4%) of the fresh sample activities after 1 and 2 freeze--thaw cycles, respectively (Fig. 1B). Long-term stability of normal control lysates stored at -80 [degrees]C was tested over a period of 12 months. The monthly mean of the normal control aliquots were stable, with an approximately 8.4% fluctuation and no trend of activity decline (Fig. 1C).


GAA product formation as a function of incubation time (15, 30, 60, 90, and 120 min) was studied with 5 leukocyte lysates. Results showed near linear increase in GAA product with incubation time (see online Supplemental Fig. 2). A 60-min incubation time was chosen for all subsequent assays, which was well within the linear range.

Ten aliquots ofnormal control pool were tested in the same assay, and the GAA activity was 61.1 (2.3) nmol x [h.sup.-1] x [mg.sup.-1] (CV of 3.7%). The same aliquots were tested in 8 different days, and the GAA activity was 57.3 (5.9) nmol x [h.sup.-1] * [mg.sup.-1] (CV of 10.3%).

The analytical range was defined as the enzyme-dependent assay response from the pooled normal control sample divided by the assay response for all GAA-independent processes (13). We anticipate that assays with a higher analytical range will be more accurate since the enzymatic activity values are spread over a larger range. In turn, we hypothesize that a high analytical range assay might be useful in distinguishing the small amounts of residual GAA activity in leukocyte lysates from IOPD, LOPD, and pseudodeficiency patients.

For MS/MS assays, the analytical range was calculated as: (GAA activity for normal control sample)--(GAA activity of the blank assay without leukocyte lysate)/(GAA activity of the assay without leukocyte lysate) (13). By using leukocyte lysates from non-Pompe pools, the analytical range for the LC-MS/MS assay of GAA was found to have a mean (SD) of 1135 (539) (see online Supplemental Table 3). The analytical range measured using fluorometry with 4-methylumbelliferyl-[alpha]-glucoside under identical assay conditions yielded a mean (SD) of 1.6 (0.1) (see online Supplemental Table 4). Thus, the analytical range for the LC-MS/MS assay was >700-fold higher than that for the fluorometric assay.


Calibration standard mixtures provided by the CDC were diluted 10-fold with methanol and analyzed directly by LC-MS/MS in triplicate. The P/IS ratio was linear from 0.05-5 with a value of [R.sup.2] of 0.9998 (see online Supplemental Fig. 3). Linearity was also tested with cell lysate mixtures. A mixing study was designed to test whether small differences in GAA activity could be distinguished at the low activity range. A lysate from fibroblasts from an IOPD patient thought to be null in GAA activity because of homozygosity of a nonsense mutation (p.R854X) in the GAA gene (Coriell repository cell line GM00338) was mixed in various proportions with a lysate from normal fibroblasts of the same protein concentration to give 0%, 1%, 2%, 5%, 10%, and 50% normal fibroblast lysate.

The GAA activity was determined by LC-MS/MS in triplicate (Table 2). The GAA activity increased linearly with the increased percentage of normal lysate protein with a [R.sup.2] = 0.9981 (Fig. 2). The mean ion counts for triplicate analysis of the blank, the 100% Pompe cell lysate, and the normal lysate were 74 [signal-to-noise ratio (S/N) of 3.6], 658 (S/N of 22.6) and 578 922, respectively. There was a widespread range of responses. Even the signal corresponding to a 0.1% of normal GAA activity in the Pompe cells was approximately 10-fold of the blank, showing that we could detect GAA well below 1% of normal. In contrast, a very high signal in blank was observed with fluorometric assay comparing to normal leukocyte control (10983 vs 17113, see online Supplemental Table 4).


A further comparative study was performed in the lysates of immortalized lymphocytes from patients with early-onset Pompe disease (EOPD) and symptomatic LOPD patients (online Supplemental Table 7 lists the Coriell database information on the donors). These cells can be expanded to provide sufficient amounts that allowed us to carry out both LC-MS/MS and fluorometric assays on the same lysates under identical conditions.

The activities of the LOPD were all higher than those for the patients with EOPD by LC-MS/MS (Fig. 3, online Supplemental Tables 5 and 6). The separation between the EOPD and LOPD LC-MS/MS GAA activities was modest. In contrast, there is no correlation in GAA activity and severity of Pompe disease using the fluorometric assay.


The normal reference range for leukocytes was established with 160 normal controls. The GAA activity [mean (SD)] was 71.2 (38.2) nmol x [h.sup.-1] x [mg.sup.-1], ranging from 23.1 to 232.0 nmol x [h.sup.-1] x [mg.sup.-1]. The mean value ofnormal controls was used to calculate the percentage of normal. The GAA activity of Pompe carriers (n = 59) was 42.8% (24.2%) of normal, ranging from 12.5-124.5 nmol x [h.sup.-1] x [mg.sup.-1]. The GAA activity of IOPD (n = 4) was 1.3% (0.8%) of normal, ranging from 0.44-1.75 nmol x [h.sup.-1] x [mg.sup.-1]. The GAA activity of LOPD (n = 19) was 4.5% (1.4%) of normal, ranging from 2.0-6.5 nmol x [h.sup.-1] x [mg.sup.-1]. The GAA activity was significantly lower in IOPD patients compared to that of the LOPD patients (P < 0.001). No overlap between IOPD and LOPD patients was observed in our cohort.

GAA activities from individuals with pseudodeficiency alleles was summarized in 3 groups based on the combinations of the 2 alleles: homozygotes for the common pseudodeficiency allele [p.G576S_E689K] (PD/PD), compound heterozygotes of a pseudodeficiency allele and a pathogenic allele (PD/Pathogenic), and compound heterozygotes of a pseudodeficiency allele and a VOUS (PD/VOUS). The GAA activity of PD/PD (n = 9), PD/Pathogenic (n = 10), and PD/VOUS (n = 7) was 8.8-28.1, 3.0-16.6 and 3.4-16.6 nmol x [h.sup.-1] x [mg.sup.-1], respectively. The mean value was 22.1%, 10.2%, and 11.6% of normal, respectively. Individuals who are homozygous of the pseudodeficiency allele clearly showed higher GAA activities than that seen in LOPD patients. However, compound heterozygotes of pseudodeficiency and a mutation (or VOUS) had some overlap with LOPD patients (Fig. 4) and most likely these patients will need careful clinical evaluation and further follow-up.

We also tested fibroblast lysates, which used to be the gold standard specimen for establishing the enzymatic diagnosis of Pompe disease. The GAA activities of 3 IOPD patients (GM00338, GM00244, and GM20122) were 0.15, 0.08, and 0.08 nmol x [h.sup.-1] x [mg.sup.-1]. The GAA activities of 2 patients with LOPD (GM11661 and GM00443) were 6.4 and 6.7 nmol x [h.sup.-1] x [mg.sup.-1]. Normal fibroblast GAA was 92.8 (89.0) nmol x [h.sup.-1] x [mg.sup.-1] (n = 10). The IOPD GAA residual activity was lower in fibroblasts than in leukocytes, possibly due to the presence of residual interfering enzymes in the leukocytes that was not completely inhibited by acarbose, but other factors cannot be ruled out. Absolute GAA activity values should not be compared across different cell types (i.e., leukocytes, fibroblasts, B-lymphocyte cell line lymphoblasts), but relative comparison of GAA activities from different patients in the same cell type is meaningful. Clear trends of separations of GAA activities in patients with IOPD vs LOPD were demonstrated in all these cell types in our study.


Here we report an LC-MS/MS method for measuring lysosomal enzyme activity in leukocytes. A key point is that the LC-MS/MS assay provides a much larger analytical range compared to the well-known fluorometric assay based on 4-methylumbelliferyl-a-glucose. The use of MS/MS vs fluorometry provides an advantage for newborn screening using dried blood spots in that a lower number of screen positives are found with equivalent cutoff values using the MS/MS platform (13). We hypothesize that this is due to the higher analytical range of the MS/MS assay. However, for accurate enzyme assays, the use of dried blood spots has a disadvantage that the measured activity cannot be normalized to the number of leukocytes (the major source of lysosomal enzymes in blood). By using purified leukocytes from blood, we can normalize the measured GAA activity to the total protein content (this is more convenient than normalizing to the number of leukocytes). This, together with the high analytical range, set the stage to explore the use of LCMS/MS with leukocytes from patients with different Pompe disease severity.

A key finding (Fig. 2) is the demonstration that the LC-MS/MS assay can readily differentiate small changes in GAA activity at the low end because of low background noise and high dynamic range with real enzymatic response signals. This is not achievable with fluorometric assay (Fig. 3) since the background signal with fluorometry substrate was very high due to the intrinsic fluorescence of the substrate itself. Therefore the correlation of residual activity measured by fluorescence to the disease severity and age of onset could only be demonstrated in cultured fibroblast samples in earlier work. With our LC-MS/MS assay this correlation can be replicated in leukocytes extracted from routine blood samples. This improvement in the accuracy of low residual activity measurement is possibly due to the large analytical range of this method.

Close to 500 GAA mutations have been documented in the human gene mutation database and there is a lack of phenotypic data for many of the mutation combinations. Therefore, prediction of Pompe disease status based on genotype is often not possible. It seems reasonable to propose that screen-positive individuals either with 2 severe GAA mutations, or individuals who have LC-MS/MS-determined leukocyte GAA activity in the range typical of patients with IOPD, should be referred for immediate clinical examination in case it is necessary to start therapy immediately. However, following up patients with LOPD and screen-positive patients with VOUS or pseudodeficiency alleles is more challenging. Pseudodeficiency alleles are particularly high in Asian populations; 3.3%-3.9% of Taiwan Chinese and Japanese individuals are homozygous for the common pseudodeficiency allele alone (p.G576S; p.E689K) (20-22). Even our LC-MS/MS GAA assay does not show complete separation between the LOPD and some patients with pseudodeficiency (Fig. 4). Thus, the LC-MS/MS GAA is a useful tool to help determine the clinical phenotype but cannot be used alone to stratify screen-positive patients for planning clinical follow-up. The enzyme findings should always be interpreted together with biomarker findings, GAA mutation status and clinical findings.

Serum creatine kinase activity is increased in the majority of cases with Pompe disease (IOPD and LOPD), and the greatest increase is usually seen in patients with IOPD. However, the creatine kinase activity can be normal in patients with LOPD before disease manifestations (4). Recently, urinary glucose tetrasaccharide (Glc4), a breakdown product from glycogen, has been used to monitor disease burden and clinical response to treatment (23-26). All of these genetic and biochemical findings should be combined with the patient's clinical findings in guiding patient care.

Fifteen of our patients in the LOPD cohort were infants identified from newborn screening and predicted to be LOPD based on nominally low residual GAA activity (approximately 5% of normal) and on 2 GAA mutations. These patients were asymptomatic at the time of blood collection. Among our cohort of patients with LOPD, only 1 adult patient (LOPD-7) was symptomatic, and the GAA activity was well within the range of our LOPD cohort. Additional study with symptomatic patients with LOPD is warranted to determine if they fall into the range reported in this study.

In conclusion, we report a LC-MS/MS assay of GAA enzymatic activity in leukocytes isolated from venous blood that displays a superior analytical range and analytical sensitivity compared to the well-known fluorometric GAA assay. The new assay differentiates patients with IOPD and LOPD in our cohort, and it also partially separates patients with LOPD from patients with pseudodeficiency.

Author Contributions: AH authors confirmed they have contributed to the intellectual content of this paper and have met the following3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: M. Caggana, New York State Department of Health; L. DiAntonio, New York State Department of Health.

Consultant or Advisory Role: M.H. Gelb, Perkin Elmer Corp.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: J.J. Orsini, NIH/NICHD contract to perform screening for Pompe disease (to the institution); M. Caggana, Eunice Kennedy Shriver National Institute of Child Health and Human Devel opment (HHSN275201400016C) and NICHD contract to conduct Pompe disease newborn screening (to the institution); E.E. Hughes, NYS Department of Health (to the institution); C. Stevens, Health Research Inc. (to the institution); L. DiAntonio, NIH/NICHD; M.P. Wasserstein, NICHD funded research to conduct pilot newborn screen for several conditions, including Pompe disease; M.H. Gelb, National Institute of Diabetes and Digestive and Kidney Diseases, NIH (R01 DK067859).

Expert Testimony: M.P. Wasserstein, served as expert witness in patent litigation case related to therapeutics for Pompe disease.

Patents: None declared.

Role of Sponsor: The funding organizations played a direct role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, and final approval of manuscript.


(1.) Kishnani PS Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry. Mol Genet Metab 2014;113:84-91.

(2.) Kishnani PS, Beckemeyer AA, Mendelsohn NJ. The new era of Pompe disease: advances in the detection, understanding of the phenotypicspectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet 2012;160:1-7.

(3.) Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6.

(4.) Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-88.

(5.) Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 2013;54:219-27.

(6.) Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-25.

(7.) Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr 2015;166:985-91.e1-2.

(8.) Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 2004;50:1785-96.

(9.) Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab 2012;106:281-6.

(10.) Sista RS, Wang T, Wu N, Graham C, Eckhardt A, Winger T, et al. Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform. Clin Chim Acta 2013;424:12-8.

(11.) Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, et al. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem 2008;54:1624-9.

(12.) Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med 2006;8:302-6.

(13.) Kumar AB, Masi S, Ghomashchi F, Chennamaneni NK, Ito M, Scott CR, et al. Tandem mass spectrometry has a larger analytical range than fluorescence assays of lysosomal enzymes: application to newborn screening and diagnosis of mucopolysaccharidoses types II, IV A, and VI. Clin Chem 2015;61:1363-71.

(14.) Okumiya T, Keulemans JL, Kroos MA, Vander Beek NM, Boer MA, Takeuchi H, et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab 2006;88:22-8.

(15.) Yang CF, Liu HC, Hsu TR, Tsai FC, Chiang SF, Chiang CC, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A 2014; 164A:54-61.

(16.) Umapathysivam K, Hopwood JJ, Meikle PJ. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Clin Chim Acta 2005;361:191-8.

(17.) Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, et al. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve 2009;40: 32-6.

(18.) Musumeci O, Thieme A, Claeys KG, Wenninger S, Kley RA, Kuhn M, et al. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum. Neuromuscul Disord 2015;25:719-24.

(19.) Montagnese F, Barca E, Musumeci O, Mondello S, Migliorato A, Ciranni A, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol 2015;262:968-78.

(20.) Shigeto S, Katafuchi T, Okada Y, Nakamura K, Endo F, Okuyama T, et al. Improved assay for differential diagnosis between Pompe disease and acid alphaglucosidase pseudodeficiency on dried blood spots. Mol Genet Metab 2011;103:12-7.

(21.) Labrousse P, Chien YH, Pomponio RJ, Keutzer J, Lee NC, Akmaev VR, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010;99:379-83.

(22.) Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet 2008;16:875-9.

(23.) An Y, Young SP, Hillman SL, Van Hove JL, Chen YT, Millington DS. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 2000;287:136-43.

(24.) An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, Chen YT. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 2005;85:247-54.

(25.) Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet CSemin Med Genet 2012; 160C:50-8.

(26.) Chien YH, Goldstein JL, Hwu WL, Smith PB, Lee NC, Chiang SC, et al. Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Rep 2015;19:67-73.

Na Lin, [1] Jingyu Huang, [1] Sara Violante, [1] Joseph J. Orsini, [2] Michele Caggana, [2] Erin E. Hughes, [2] Colleen Stevens, [2] Lisa DiAntonio, [2] Hsuan Chieh Liao, [4,5] Xinying Hong, [4,5] Farideh Ghomashchi, [4,5] Arun Babu Kumar, [4,5] Hui Zhou, [3] Ruth Kornreich, [1] Melissa Wasserstein, [1] Michael H. Gelb, [4,5] * and Chunli Yu [1] *

[1] Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY; [2] Laboratory of Human Genetics, New York State Department of Health, Wadsworth Center, Albany, NY; [3] Newborn Screening Translation Research Initiative, National Foundation for the Centers for Disease Control and Prevention, Inc., Atlanta, GA; Departments of [4] Chemistry and [5] Biochemistry, University of Washington, Seattle, WA.

* Address correspondence to: C.Y. at Mount Sinai GeneticTesting Laboratory, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1497, New York, NY 10029-6574. Fax 212-241-0139; e- mail M.H.G. at Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195. Fax 206-685-8665; e-mail

Received April 14, 2016; accepted January 11, 2017.

Previously published online at DOI: 10.1373/clinchem.2016.259036

[6] Nonstandard abbreviations: PD, Pompe disease; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; GAA, lysosomal acid a-glucosidase; MS/MS, tandem mass spectrometry; VOUS, variants of unknown significance; S, substrate; IS, internal standard; P, product; RBC, red blood cell; S/N, signal-to-noise ratio; EOPD, early-onset Pompe disease; PD/PD, pseudodeficiency/pseudodeficiency; PD/Pathogenic, pseudodeficiency/pathogen mutation; PD/VOUS, pseudodeficiency/VOUS.

Caption: Fig. 1. GAA stability studies under different conditions. (A) GAA stability in blood stored at ambient temperature followed by leukocyte preparation on days 0,1, 2, 3,4, and 5 (n = 4); (B) GAA stability of lysate with 1 and 2 freeze thaw cycles (n = 9); (C) GAA long-term stability of lysate stored at -80 [degrees]C (n = 2-5 for each month). Error bars represent the SDs.

Caption: Fig. 2. Observed GAA activity as a function of the fraction of non- Pompe fibroblast protein added to IOPD fibroblasts. Thexaxis shows the expected percentage of normal or equivalently the percent of normal cell protein in the normal cell/IOPD cell mixture. The inset shows a blowup of the low-end range. Error bars are the SDs from triplicate analyses.

Caption: Fig. 3. GAA activities of EOPD and LOPD in immortalized B-lymphocytes. (A), Results analyzed by LC-MS/MS. (B), Results analyzed byfluorometry with 4-methylumbelliferyl-a-glucoside under identical assay conditions [same buffer and incubation conditions but with the MS/MS or the 4-methylumbelliferone substrates, appropriately (see the online Supplemental Material)]. Error bars are the SDs from triplicate analyses.

Caption: Fig. 4. Dot scatter plot of GAA activity in IOPD, LOPD, pseudodeficiency patients, and carriers. The pseudodeficiency patients are divided into 3 groups: homozygotes of the common pseudodeficiency allele [p.G576S_E689K] (PD/PD), compound heterozygotes of a pseudodeficiency allele and a pathogenic allele (PD/Pathogenic), and compound heterozygotes of a pseudodeficiency allele and a VOUS (PD/VOUS). In comparison, the normal GAA activity was 71.3 (38.2), ranging from 23.1 to 232.0 nmol x [h.sup.-1] x [mg.sup.-1].
Table 1. GAA activities in patients with IOPD, LOPD, and
pseudodeficiency alleles.

                                     GAA (a)
ID                    Age      (nmol x [h.sup.-1]    Mean, %
                                 x [mg x sup.-1])

IOPD-1             5.5 years           0.9           1.2
IOPD-2              10 days            1.8           2.5
IOPD-3             2 months            0.4           0.6
IOPD-4             3 months            0.6           0.9
LOPD-1              3 weeks            3.2           4.5
LOPD-2              2 weeks            3.2           4.5
LOPD-3              2 weeks            2.7           3.7
LOPD-4             28 years            3.4           4.7
LOPD-5              2 weeks            3.1           4.4
LOPD-6             32 years            3.6           5.1
LOPD-7             24 years            4.0           5.6
LOPD-8              6 weeks            2.9           4.1
LOPD-9              3 weeks            4.1           5.8
LOPD-10             2 weeks            2.5           3.6
LOPD-11            8.3 years           2.0           2.8
LOPD-12             2 weeks            2.0           2.8
LOPD-13             2 weeks            2.6           3.7
LOPD-14             2 weeks            3.0           4.2
LOPD-15             2 weeks            3.6           5.1
LOPD-16            2.5 weeks           2.5           3.6
LOPD-17             6 weeks            6.5           9.2
LOPD-18             2 weeks            2.9           4.0
LOPD-19             2 weeks            2.7           3.8
PD/Pathogenic-1     5 weeks           16.6           23.2
PD/Pathogenic-2     3 weeks            8.8           12.4
PD/Pathogenic-3     2 weeks            4.9           6.9
PD/Pathogenic-4     2 weeks            5.0           7.0
PD/Pathogenic-5     4 weeks            6.5           9.1
PD/Pathogenic-6     4 weeks            8.8           12.3
PD/Pathogenic-7     2 weeks            3.0           4.2
PD/Pathogenic-8     2 weeks            5.0           7.0
PD/Pathogenic-9     3 weeks            8.4           11.7
PD/Pathogenic-10    2 weeks            5.5           7.8
PD/VOUS-1           3 weeks            3.6           5.0
PD/VOUS-2           2 weeks           16.6           23.3
PD/VOUS-3           2 weeks           11.3           15.8
PD/VOUS-4           2 weeks            5.3           7.5
PD/VOUS-5          1.7 years          9.16           12.9
PD/VOUS-6           2 weeks           8.26           11.6
PD/VOUS-7           3 weeks           3.43           4.8
PD/PD-1              Adult            18.7           26.2
PD/PD-2              Adult            17.4           24.4
PD/PD-3              Adult            10.5           14.8
PD/PD-4              Adult             9.4           13.2
PD/PD-5              Adult            12.3           17.3
PD/PD-6              Adult             8.8           12.3
PD/PD-7              Adult            14.9           20.9
PD/PD-8              Adult            28.1           39.4
PD/PD-9              Adult            21.6           30.3
Normal range                   71.2 [+ or -] 38.2
Carrier range                  30.5 [+ or -] 17.3

ID                 Mutation (a)

IOPD-1             NA (b)
IOPD-2             p.P285R//p.P768L
IOPD-3             p.D399VfsX6//p.D399VfsX6
IOPD-4             p.D91N_p.C103G//p.G334C
LOPD-1             c.-32-13T>G//c.-32-13T>G
LOPD-2             c.-32-13T>G//c.-32-13T>G
LOPD-3             c.2647-7G>A//c.2647-7G>A
LOPD-4             c.-32-13T>G//c.-32-13T>G
LOPD-5             c.-32-13T>G//c.-32-13T>G
LOPD-6             c.-32-13T>G//c.-32-13T>G
LOPD-7             c.-32-13T>G//p.G828_N882del
LOPD-8             p.P684L//p.E689K_p.W746C
LOPD-9             p.R89 //p.E176fsX45
LOPD-10            p.M173del//p.A237V
LOPD-11            c.-32-13T>G//p.Q743 *
LOPD-12            c.-32-13T>G//p.V350 mol/L
LOPD-13            c.-32-13T>G// P684L
LOPD-14            c.-32-13T>G//p.R837C
LOPD-15            p.D91N_p.V740GfsX55//.T234 mol/L
LOPD-16            c.-32-13T>G//p.E689K_p.W746C
LOPD-17            c.-32-13T>G//c.1552-3C>G
LOPD-18            c.-32-13T>G//p.E730X
LOPD-19            c.-32-13T>G//p.H372L
PD/Pathogenic-1    p.G576S_p.E689K//p.S251L_p.S254L
PD/Pathogenic-2    p.G576S_p.E689K//c.2646+2T>A
PD/Pathogenic-3    p.G576S_p.E689K//p.S251L_p.S254L
PD/Pathogenic-4    p.G576S_p.E689K//p.S251L_p.S254L
PD/Pathogenic-5    p.G576S_p.E689K//c.-32-13T>G
PD/Pathogenic-6    p.G576S_p.E689K//p.N87TfsX55
PD/Pathogenic-7    p.G576S_p.E689K//p.V723M
PD/Pathogenic-8    p.G576S_p.E689K//c.692+5G>T
PD/Pathogenic-9    p.G576S_p.E689K//p.E888X
PD/Pathogenic-10   p.D91N//p.E721rf*_p.W746L
PD/VOUS-1          p.G576S_p.E689K//p.V222M
PD/VOUS-2          p.G576S_p.E689R//p.P690L
PD/VOUS-3          p.G576S_p.E689K//o.V222M
PD/VOUS-4          p.G576S_p.E689K//p.V222M
PD/VOUS-5          p.G576S_p.E689K//p.P475L
PD/VOUS-6          p.G576S_p.E689K//p.P768S
PD/VOUS-7          p.G576S_p.E689K//p.G615R
PD/PD-1            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-2            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-3            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-4            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-5            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-6            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-7            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-8            p.G576S_p.E689K//p.G576S_p.E689K
PD/PD-9            p.G576S_p.E689K//p.G576S_p.E689K
Normal range

Carrier range

(a) Red text indicates pathogenic mutation; green, VOU; blue,
pseudodeficiency allele.

(b) NA, not applicable.

Table 2. Linear GAA activity responses in fibroblast mixtures
(nmol x [h.sup.-1] x [mg.sup.-1]).

Expected proportion      Run 1   Run 2   Run 3   Mean    SD    % of

100% Pompe (GM00338)     0.1     0.1     0.2     0.1     0.0   0.12
99% Pompe + 1% normal    1.4     1.4     1.4     1.4     0.0   1.1
98% Pompe + 2% normal    2.6     2.4     2.7     2.6     0.1   2.1
95% Pompe + 5% normal    6.4     6.7     6.7     6.6     0.2   5.4
90% Pompe + 10% normal   12.6    13.9    13.6    13.3    0.6   11.0
50% Pompe + 50% normal   61.6    69.0    69.3    66.6    3.5   54.8
100% Normal (GM23971)    122.1   121.7   121.1   121.6   0.4   100.0
COPYRIGHT 2017 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Automation and Analytical Techniques
Author:Lin, Na; Huang, Jingyu; Violante, Sara; Orsini, Joseph J.; Caggana, Michele; Hughes, Erin E.; Steven
Publication:Clinical Chemistry
Article Type:Report
Date:Apr 1, 2017
Previous Article:Multicenter Evaluation of Cystatin C Measurement after Assay Standardization.
Next Article:Closed-Tube PCR with Nested Serial Invasion Probe Visualization Using Gold Nanoparticles.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters